Drug news
Boehringer files nintedanib at FDA for Idiopathic Pulmonary Fibrosis
The NDA submitted by Boehringer for nintedanib has been accepted for filing by the FDA and granted Priority Review designation. The application for nintedanib is currently under review for the treatment of people with Idiopathic Pulmonary Fibrosis (IPF). The NDA package includes results from two global Phase III studies (INPULSIS-1 and INPULSIS-2.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.